ArticleCardiovascular and interventional radiology2026
Superselective Pulmonary Artery Embolization for Refractory Massive Hemoptysis Post-Bronchial Artery Embolization: A Bail-Out Measure.
Article in Cardiovascular and interventional radiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThe objective of the study was to evaluate the outcomes of segmental/subsegmental superselective pulmonary artery embolization (PAE) as a measure to control refractory hemoptysis after bronchial artery embolization (BAE). MATERIAL AND
methodsIt was a prospective case series with subset analysis. Between January 2022 and July 2024, 50 patients with recurrent hemoptysis after BAE were evaluated using CT angiography. If major systemic arterial supply was identified, repeat BAE was performed for recanalized or new arteries (34/50 patients). Persistent systemic-to-pulmonary shunts (SPS) (identified using CTA and diagnostic arteriograms) were treated with selective PAE using microcoils (in 7 patients out of 34). Four were males, 3 females; ages 20-55 years. Six out of 7 patients had chronic pulmonary aspergillosis and one had post-tuberculosis sequelae. Most patients had undergone multiple prior BAE procedures (2-3 sessions; embolizing 2-8 arteries). No aneurysms or other vascular anomalies were identified in the selected pulmonary artery branches. All were on appropriate medical management for their underlying disease. Technical success was assessed by occlusion of the target pulmonary artery branch. Clinical outcomes were assessed by immediate control of hemoptysis with no recurrence of massive bleed in the follow-up period of 6-12 months.
resultsSPS was localized to the left upper lobe (4 patients), left lower lobe (1), right lower lobe (1), and right upper lobe (1) in the diseased regions. Bronchial arteries supplied systemic flow in 3 patients, while non-bronchial systemic arteries (NBSAs) were involved in 4 patients (more than one vessel supply was identified in two cases). In 4 patients, only one selective branch of PA was embolized using microcoils; in three patients, two separate branches were embolized. Technical success was 100%, with effective control of hemoptysis in all cases. One patient had mild hemoptysis after two weeks, managed with intravenous voriconazole and oral tranexamic acid. No complications were observed.
conclusionSuperselective PAE may be considered as a safe and effective bail-out measure for refractory massive hemoptysis persisting after BAE in selected patients. [Level of Evidence: Level 3, Non-randomized controlled cohort].
Indexed as
Identifiers
41692834What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.